Everolimus

依维莫司

Report date: 2026/04/08 20:02:35
NME

Base Information

Drug NameEverolimus
Drug Alias Name伊维莫司Everolimusum依维霉素Synergy依维莫斯 +[17] 
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionmTOR Complex 2 inhibitorsMammalian target of Rapamycin (mTORC1) inhibitors
TargetsMammalian target of Rapamycin (mTORC1)mTOR Complex 2
Therapy Area/IndicationsRejection of organ transplantationRejection of renal transplantationRejection of lung transplantation +[136] 
Global Approved IndicationsRejection of organ transplantationRejection of renal transplantationPancreatic neuroendocrine tumors (pNET) +[14] 
Approved Indications in ChinaKidney Neoplasms
Original Approved Country/TerritorySweden
Original Approved Date2003/07/18
Country/TerritoryCzechiaBelgiumBulgaria +[45] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesNovartis Pharma Ag
China Registration ClassN/A

Develop Information

Active CompaniesUniversity Of California San FranciscoUniversity of Texas Southwestern Medical CenterUniversity of Zurich +[18] 
Inactive CompaniesUtah State UniversityDana-Farber Cancer InstituteInstitut National De La Santé Et De La Recherche Médicale, France U979 +[37] 
Active IndicationsRejection of organ transplantationRejection of renal transplantationPancreatic neuroendocrine tumors (pNET) +[38] 
Inactive IndicationsRejection of lung transplantationMetastatic breast cancerSkin Melanoma +[98] 

Other Information

ATC CodeL01EG02L04AH02
Related LinksN/A